High CD200 expression is associated with poor prognosis in cytogenetically normal acute myeloid leukemia, even in FlT3-ITD-/NPM1+ patients.

[1]  S. Aref,et al.  Upregulation of CD200 is associated with regulatory T cell expansion and disease progression in multiple myeloma , 2017, Hematological oncology.

[2]  Jian-yong Li,et al.  Low expression of CD200 predicts shorter time-to-treatment in chronic lymphocytic leukemia , 2016, Oncotarget.

[3]  R. Fanin,et al.  Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors , 2015, Oncotarget.

[4]  Daoxin Ma,et al.  The Profile of T Helper Subsets in Bone Marrow Microenvironment Is Distinct for Different Stages of Acute Myeloid Leukemia Patients and Chemotherapy Partly Ameliorates These Variations , 2015, PloS one.

[5]  A. Burnett,et al.  The immunosuppressive ligands PD-L1 and CD200 are linked in AML T-cell immunosuppression: identification of a new immunotherapeutic synapse , 2015, Leukemia.

[6]  H. Dombret,et al.  Contribution of CD39 to the immunosuppressive microenvironment of acute myeloid leukaemia at diagnosis , 2014, British journal of haematology.

[7]  J. Esteve,et al.  Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. , 2013, Blood.

[8]  Ø. Bruserud,et al.  The angioregulatory cytokine network in human acute myeloid leukemia - from leukemogenesis via remission induction to stem cell transplantation. , 2012, European cytokine network.

[9]  W. Tse,et al.  Th17 related cytokines in acute myeloid leukemia. , 2012, Frontiers in bioscience.

[10]  L. Meyaard,et al.  CD200R signaling in tumor tolerance and inflammation: A tricky balance. , 2012, Current opinion in immunology.

[11]  R. Hills,et al.  Increased CD200 expression in acute myeloid leukemia is linked with an increased frequency of FoxP3+ regulatory T cells , 2012, Leukemia.

[12]  R. Hills,et al.  Expression of CD200 on AML blasts directly suppresses memory T-cell function , 2012, Leukemia.

[13]  P. Hari,et al.  CD200 expression in plasma cell myeloma , 2011, British journal of haematology.

[14]  Ash A. Alizadeh,et al.  CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells , 2009, Cell.

[15]  R. Fanin,et al.  Two novel NPM1 mutations in a therapy‐responder AML patient , 2009, Hematological oncology.

[16]  T. Whiteside,et al.  Increased Frequency and Suppression by Regulatory T Cells in Patients with Acute Myelogenous Leukemia , 2009, Clinical Cancer Research.

[17]  M. Hallek,et al.  Disruption of T cell suppression in chronic lymphocytic leukemia by CD200 blockade. , 2009, Leukemia research.

[18]  C. Tato,et al.  Alternative lifestyles of T cells , 2008, Nature Immunology.

[19]  W. Farrar,et al.  Cancer stem cells, CD200 and immunoevasion. , 2008, Trends in immunology.

[20]  R. Hills,et al.  CD200 as a prognostic factor in acute myeloid leukaemia , 2007, Leukemia.

[21]  T. Rème,et al.  CD200 is a new prognostic factor in multiple myeloma. , 2006, Blood.

[22]  Shiang Huang,et al.  Increased population of CD4+CD25high regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients , 2005, European journal of haematology.

[23]  F. Mandelli,et al.  Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol , 2002, Leukemia.

[24]  C. Bloomfield,et al.  Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). , 2002, Blood.

[25]  H. Prentice,et al.  Acute myeloid leukaemia cells secrete a soluble factor that inhibits T and NK cell proliferation but not cytolytic function – implications for the adoptive immunotherapy of leukaemia , 2001, Clinical and experimental immunology.

[26]  G. Mufti,et al.  Microenvironment Produced by Acute Myeloid Leukemia Cells Prevents T Cell Activation and Proliferation by Inhibition of NF-κB, c-Myc, and pRb Pathways , 2001, The Journal of Immunology.

[27]  G. Tate,et al.  CD200 Expression on Plasma Cell Myeloma Cells is Associated with the Efficacies of Bortezomib, Lenalidomide and Thalidomide. , 2015, Journal of clinical and experimental hematopathology : JCEH.

[28]  B. Barlogie,et al.  Diagnostic usefulness and prognostic impact of CD200 expression in lymphoid malignancies and plasma cell myeloma. , 2012, American journal of clinical pathology.

[29]  Bob Löwenberg,et al.  Review Articles (434 articles) , 2008 .

[30]  I. A. Vorob’ev,et al.  [Characteristics of T-cell immunity in patients with acute leukemia]. , 2006, Terapevticheskii arkhiv.

[31]  J. Kolls,et al.  Interleukin 17: An example for gene therapy as a tool to study cytokine mediated regulation of hematopoiesis , 2002, Journal of cellular biochemistry. Supplement.